Aventis Lovenox patents
Executive Summary
Aventis will not file patent infringement lawsuit against Amphastar to enforce Lovenox patent No. 4,692,435, set to expire in December 2004. Aventis' defense against enoxaparin generics is focused on the re-issuance of another patent (No. 5,389,618) that will expire in February 2012. The company received a 30-month stay of approval based on a suit against Amphastar and Teva on the original '618 patent (1"The Pink Sheet" Aug. 18, 2003, p. 16)...
You may also be interested in...
Aventis Lovenox Patent Defense: Re-Issuance Higher Priority Than Stay
Aventis' Lovenox generic defense remains centered on the re-issuance of an enoxaparin patent as the company defends the original version against potential generic competition
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.